IR.CHIASMAPHARMA.COM

Chiasma

You are using an outdated. Browser. Please upgrade your browser. To improve your experience. Chiasma is a biopharmaceutical company focused on improving the lives of patients who face challenges associated with existing treatments for their rare and debilitating diseases. Employing its Transient Permeability Enhancer (TPE. For the potential treatment of adults with acromegaly. Chiasma Provides Year-End Corporate Update and Preliminary Outlook for 2017. Learn about Chiasma’s corporate mission and values.

http://ir.chiasmapharma.com/

OVERVIEW OF ir.chiasmapharma.com

TRAFFIC RANK

>1,000,000

REVIEWS

0

PAGES IN THIS WEBSITE

16

LINKS TO THIS WEBSITE

CONTACTS

ADDRESSES

SOCIAL LINKS

ONLINE SINCE

WEBSITE DETAILS

SEO

PAGES

SIMILAR SITES

TRAFFIC RANK FOR IR.CHIASMAPHARMA.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

August

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Sunday

TRAFFIC BY CITY

Sign up

CUSTOMER REVIEWS

Average Rating: 4.8 out of 5 with 10 reviews

5 star

8

4 star

2

3 star

0

2 star

0

1 star

0

Hey there! Start your review of ir.chiasmapharma.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

LOAD TIME

0.6 seconds

FAVICON PREVIEW

16x16

CONTACTS AT IR.CHIASMAPHARMA.COM

ADD CONTACT

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

PAGES IN
THIS WEBSITE

16

SSL

EXTERNAL LINKS

34

SITE IP

72.47.238.89

LOAD TIME

0.641 sec

SCORE

6.2

PAGE TITLE

Chiasma | ir.chiasmapharma.com Reviews

<META> DESCRIPTION

You are using an outdated. Browser. Please upgrade your browser. To improve your experience. Chiasma is a biopharmaceutical company focused on improving the lives of patients who face challenges associated with existing treatments for their rare and debilitating diseases. Employing its Transient Permeability Enhancer (TPE. For the potential treatment of adults with acromegaly. Chiasma Provides Year-End Corporate Update and Preliminary Outlook for 2017. Learn about Chiasma’s corporate mission and values.

<META> KEYWORDS

1 jump to navigation

2 mission and values

3 management team

4 board of directors

5 clinical advisors

6 octreotide capsules

7 clinical trials

8 technology

9 patients

10 about acromegaly

CONTENT

Page content here

KEYWORDS ON PAGE

jump to navigation,mission and values,management team,board of directors,clinical advisors,octreotide capsules,clinical trials,technology,patients,about acromegaly,about treatment,news and investors,press releases,events and presentations,annual meeting

SERVER

nginx

POWERED BY

PleskLin

CONTENT-TYPE

utf-8

GOOGLE PREVIEW

Chiasma | ir.chiasmapharma.com Reviews

https://ir.chiasmapharma.com

You are using an outdated. Browser. Please upgrade your browser. To improve your experience. Chiasma is a biopharmaceutical company focused on improving the lives of patients who face challenges associated with existing treatments for their rare and debilitating diseases. Employing its Transient Permeability Enhancer (TPE. For the potential treatment of adults with acromegaly. Chiasma Provides Year-End Corporate Update and Preliminary Outlook for 2017. Learn about Chiasma’s corporate mission and values.

INTERNAL PAGES

ir.chiasmapharma.com

1

About Acromegaly | Chiasma

http://www.ir.chiasmapharma.com/about-acromegaly

You are using an outdated. Browser. Please upgrade your browser. To improve your experience. Common features of acromegaly are facial changes, intense headaches, joint pain, impaired vision and enlargement of the hands, feet, tongue and internal organs. Serious health conditions associated with the progression of acromegaly include type 2 diabetes, hypertension, respiratory disorders and cardiac and cerebrovascular disease.

2

Patients & Families | Chiasma

http://www.ir.chiasmapharma.com/patients-families

You are using an outdated. Browser. Please upgrade your browser. To improve your experience. At Chiasma, we are focused on helping patients who suffer from conditions that require chronic injections, by developing product candidates based on our proprietary Transient Permeability Enhancer (TPE ) technology platform. We are developing octreotide capsules for the potential treatment of acromegaly in adults with acromegaly.

3

Clinical Advisors | Chiasma

http://www.ir.chiasmapharma.com/clinical-advisors

You are using an outdated. Browser. Please upgrade your browser. To improve your experience. Our team of advisors includes academic and clinical leaders with world-renowned reputations in the field of endocrinology. Shlomo Melmed, MD. Senior Vice President, Academic Affairs, Dean of. Christian J. Strasburger, MD. Professor of Medicine, Chief, Division of.

4

Chiasma's Product Development Effort | Chiasma

http://www.ir.chiasmapharma.com/products

You are using an outdated. Browser. Please upgrade your browser. To improve your experience. Chiasma's Product Development Effort. Chiasma is focused on improving the lives of patients who face challenges associated with existing treatments for their rare and debilitating diseases. The company's proprietary Transient Permeability Enhancer (TPE ) technology platform is designed to enable the intestinal absorption of molecules that would otherwise have limited intestinal bioavailability.

5

Chiasma Careers | Chiasma

http://www.ir.chiasmapharma.com/node/9

You are using an outdated. Browser. Please upgrade your browser. To improve your experience. Submissions for this form are closed. We employ high-energy team players who are both passionate about their work and compassionate for the patients we serve. We require innovative thinkers who enjoy rolling up their sleeves, thrive within a fast-moving environment and conduct themselves with the utmost integrity. Review our open US.

UPGRADE TO PREMIUM TO VIEW 11 MORE

TOTAL PAGES IN THIS WEBSITE

16

LINKS TO THIS WEBSITE

chiasmapharma.com

About Chiasma | Chiasma

http://www.chiasmapharma.com/node/1

You are using an outdated. Browser. Please upgrade your browser. To improve your experience. Chiasma is dedicated to improving the lives of patients who face challenges associated with existing treatments for their rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE. The company is now conducting an additional international Phase 3 trial on Mycapssa in acromegaly designed to support a potential Marketing Authorization Application with the European Medicines Agency. Chias...

chiasmapharma.com

Chiasma's Product Development Effort | Chiasma

http://www.chiasmapharma.com/transformational-products

You are using an outdated. Browser. Please upgrade your browser. To improve your experience. Chiasma's Product Development Effort. Chiasma is focused on improving the lives of patients by developing and ultimately commercializing oral therapies that eliminate the significant limitations and burdens generally associated with therapies that are currently only available as injections. The company's proprietary Transient Permeability Enhancer (TPE. Chiasma’s lead investigational candidate, Mycapssa.

chiasmapharma.com

Our Mission | Chiasma

http://www.chiasmapharma.com/transformational-mission

You are using an outdated. Browser. Please upgrade your browser. To improve your experience. At Chiasma, we are focused on improving the lives of patients suffering from orphan diseases by developing and ultimately commercializing novel oral therapies that are available today only by injection. We are guided every day by our strongly held values:. For the patients we serve. In applying our proprietary Transient Permeability Enhancer (TPE. Terms of Use (Updated).

chiasmapharma.com

Octreotide Capsules | Chiasma

http://www.chiasmapharma.com/node/16

You are using an outdated. Browser. Please upgrade your browser. To improve your experience. Chiasma's octreotide capsules, which are are conditionally trade named Mycapssa. Are being developed for the treatment of acromegaly, a rare, debilitating disease typically caused by a benign tumor of the pituitary gland that releases excess growth hormone (GH), leading to excess growth of certain parts of the body. For Investigational Use Only. Product Not Available for Commercial Distribution.

chiasmapharma.com

Publications | Chiasma

http://www.chiasmapharma.com/publications

You are using an outdated. Browser. Please upgrade your browser. To improve your experience. Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial. J Clin Endocrinol Metab. 2015; doi: 10.1210/jc.2014-4113. A Novel Suspension Formulation Enhances Intestinal Absorption of Macromolecules Via Transient and Reversible Transport Mechanisms. J Clin Endocrinol Metab. Terms of Use (Updated).

chiasmapharma.com

About Chiasma | Chiasma

http://www.chiasmapharma.com/chiasma

You are using an outdated. Browser. Please upgrade your browser. To improve your experience. Chiasma is dedicated to improving the lives of patients who face challenges associated with existing treatments for their rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE. The company is now conducting an additional international Phase 3 trial on Mycapssa in acromegaly designed to support a potential Marketing Authorization Application with the European Medicines Agency. Chias...

chiasmapharma.com

Chiasma Careers | Chiasma

http://www.chiasmapharma.com/careers

You are using an outdated. Browser. Please upgrade your browser. To improve your experience. Submissions for this form are closed. At Chiasma, we are focused on transforming treatment paradigms and improving patients’ lives by developing and ultimately commercializing novel oral medications that are currently available only by injection. We offer competitive compensation, a comprehensive benefits package and a tremendous opportunity for advancement. Review our open US. Terms of Use (Updated).

chiasmapharma.com

Board of Directors | Chiasma

http://www.chiasmapharma.com/board-directors

You are using an outdated. Browser. Please upgrade your browser. To improve your experience. Chairman of the Board. Ansbert Gadicke, MD. Bard Geesaman, MD, PhD. John A. Scarlett, MD. John F. Thero. James R. Tobin. Terms of Use (Updated).

chiasmapharma.com

Patients & Families | Chiasma

http://www.chiasmapharma.com/patients-families

You are using an outdated. Browser. Please upgrade your browser. To improve your experience. Chiasma is committed to developing new, innovative solutions to revolutionize the course of treatment for patients with rare and serious chronic diseases. Chiasma is currently developing Mycapssa. Chiasma is now conducting an additional international Phase 3 trial of Mycapssa in acromegaly designed to support a potential Marketing Authorization Application with the European Medicines Agency. Terms of Use (Updated).

UPGRADE TO PREMIUM TO VIEW 25 MORE

TOTAL LINKS TO THIS WEBSITE

34

OTHER SITES

ir.checkpointsystems.com

Overview | Investor Relations | Checkpoint Systems

Alpha High Theft Solutions. Become a Channel Partner. Find a Channel Partner. Articles and Success Stories. White Papers and Studies. Sustainability and Social Responsibility. Checkpoint at a Glance. Checkpoint at a Glance. Send to a colleague. Checkpoint Systems is a global leader in merchandise availability solutions for the retail industry, encompassing loss prevention. Q2 2015 Checkpoint Systems Earnings Conference Call. 160;at 8:30 am ET. Q2 2015 Checkpoint Systems Earnings Conference Call. Checkpoi...

ir.checkpointtx.com

Overview | Checkpoint Therapeutics

SEC Filings and Financials. SEC Filings and Financials. Checkpoint Therapeutics Initiates Phase 1/2 Study of CK-101 A Novel Third-Generation EGFR Inhibitor. Checkpoint Therapeutics to Present at the Ladenburg Thalmann 2nd Annual Healthcare Conference. Checkpoint Therapeutics Announces Acceptance of IND Application for CK-101 A Novel Third Generation EGFR Inhibitor. Checkpoint Therapeutics, Inc. New York, NY 10014. S&P Global Market Intelligence. TERMS AND CONDITIONS OF USE. These Terms of Use are the ent...

ir.chem.cmu.edu

ChemCollective

Online Resources for Teaching and Learning Chemistry. We've recently updated our site. If you are having problems, you can click here to get to the old site. Resources to Teach and Learn Chemistry. The ChemCollective is a collection of virtual labs. Qualitative and Quantitative Analysis of Food Dyes. Release of new HTML5 Virtual Lab. Kinetics of Bleaching of Food Dyes Activity. The ChemCollective site and its contents are licensed under a Creative Commons Attribution 3.0 NonCommercial-NoDerivs License.

ir.chemed.com

Chemed Corporation | Investor Relations | Investor Relations Home

Q2 2015 Chemed Corporation Earnings Conference Call. 160;at 10:00 am ET. Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation operates two wholly owned subsidiaries: VITAS Healthcare Corporation. VITAS is the nation's largest provider of end-of-life hospice care and Roto-Rooter is the nation's leading provider of plumbing and drain cleaning services. Chemed Corporation Increases Quarterly Dividend. Chemed Reports Second-Quarter 2015 Results. 160; 1.04.

ir.chemocentryx.com

Overview | ChemoCentryx, Inc.

Skip to main navigation. Great Science. Great Medicine. Orphan and Rare Diseases. Immuno-Oncology and Other Therapeutic Areas. Other Inflammatory and Autoimmune Diseases. Th17 Driven Diseases and CCR6. Orphan and Rare Diseases. Other Inflammatory and Autoimmune Diseases. Orphan and Rare Diseases. Immuno-Oncology and Other Therapeutic Areas. Other Inflammatory and Autoimmune Diseases. Th17 Driven Diseases and CCR6. Orphan and Rare Diseases. Other Inflammatory and Autoimmune Diseases. View all news releases.

ir.chiasmapharma.com

Chiasma

You are using an outdated. Browser. Please upgrade your browser. To improve your experience. Chiasma is a biopharmaceutical company focused on improving the lives of patients who face challenges associated with existing treatments for their rare and debilitating diseases. Employing its Transient Permeability Enhancer (TPE. For the potential treatment of adults with acromegaly. Chiasma Provides Year-End Corporate Update and Preliminary Outlook for 2017. Learn about Chiasma’s corporate mission and values.

ir.chimerix.com

Investor Overview - Chimerix, Inc.

Discovery and Clinical Trials. Annual Reports and Proxies. 4:00 P ET on 08/14/15. 097 (- 1.90%). Delayed at least 20 minutes. August 6, 2015. Chimerix Announces Second Quarter 2015 Financial Results. August 3, 2015. Chimerix Completes Targeted Enrollment for Brincidofovir Phase 3 AdVise Trial for Adenovirus Infection. July 30, 2015. Chimerix to Announce Second Quarter 2015 Financial Results on August 6, 2015. View all press releases ». August 6, 2015 at 8:30 AM ET.

ir.china-embassy.org

Embassy of the People's Republic of China in the Islamic Republic of Iran

ir.chinacache.com

ChinaCache International Holdings Ltd. - Investor Relations

Rsaquo; Investor Relations. ABOUT US / OUR BUSINESS. ChinaCache is the leading total solutions provider of Internet content and application delivery services in China, including Internet data center operations and Internet exchange centers. We provide a portfolio of services and solutions to businesses, government agencies and other enterprises to enhance the reliability and scalability of their online services and applications and improve end-user experience. View all ». Feb 7, 2018. Dec 21, 2017.

ir.chinacast.com.cn

域名售卖

ir.chinacordbloodcorp.com

China Cord Blood Corporation - Investor Relations -Investor Relations Home

About Cord Blood Banking. Clinical Benefits of Cord Blood Stem Cells. Cord Blood Bank FAQ. China Cord Blood Corporation. 06 Aug. 2015. China Cord Blood Corporation Announces Receipt of Non-Binding Acquisition Proposal. 31 Jul. 2015. China Cord Blood Corporation Files Its Annual Report on Form 20-F. 19 Jun. 2015. China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2015. 09 Jun. 2015. Annual Report for Fiscal Year 2015 (20-F). 160; 0.28. 06 Aug. 2015. Data ...